Research & Development
60° Pharmaceuticals passes US FDA's priority review designation for malaria drug Tafenoquine
9 February 2018 -

New medicines company 60 Degrees Pharmaceuticals (60P) reported on Thursday the receipt of the US Food and Drug Administration's (USFDA) priority review designation for the New Drug Application (NDA) for Tafenoquine (TQ) for the prevention of malaria in adults.

In January 2018, the company was awarded the USFDA 's Fast Track Designation for the use of Tafenoquine to prevent malaria in adults travelling to areas where the disease is prevalent. Since malaria is the top infectious disease threat to US.Military service members overseas, the military maintains a robust anti-malarial drug development effort through internal research and commercial partnerships.

According to the company, an analysis of five clinical trials to assess the safety and tolerability of Tafenoquine has been published in Travel Medicine and Infectious Disease, a peer reviewed journal. Tafenoquine appeared to be safe and well tolerated when the anticipated clinical regimen (ACR) was administered.

Malaria, a life-threatening disease transmitted through the bite of an infected mosquito, poses a significant risk to millions of healthy individuals travelling in many parts of the world, including employees of non-governmental organisations, casual vacationers, industrial and business workers and military forces.